首页> Frontiers in immunology> Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients.

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： Eleonora,Lekova

第一单位： Immunology Research Unit, GlaxoSmithKline Research & Development (GSK R&D), Stevenage, United Kingdom.

作者： Eleonora,Lekova ^[1] ; Wioleta M,Zelek ^[2] ; David,Gower ^[3] ; Claus,Spitzfaden ^[4] ; Isabelle H,Osuch ^[1] ; Elen,John-Morris ^[1] ; Lasse,Stach ^[3] ; Darren,Gormley ^[1] ; Andrew,Sanderson ^[5] ; Angela,Bridges ^[5] ; Elizabeth R,Wear ^[1] ; Sebastien,Petit-Frere ^[1] ; Michael N,Burden ^[3] ; Richard,Priest ^[3] ; Trevor,Wattam ^[3] ; Semra J,Kitchen ^[1] ; Maria,Feeney ^[1] ; Susannah,Davis ^[3] ; B Paul,Morgan ^[2] ; Eva-Maria,Nichols ^[1]

作者单位： Immunology Research Unit, GlaxoSmithKline Research & Development (GSK R&D), Stevenage, United Kingdom. ^[1] Division of Infection and Immunity and Dementia Research Institute, Systems Immunity Research Institute, School of Medicine, Cardiff University, Wales, United Kingdom. ^[2] Medicinal Science and Technology, Biopharm Discovery, GlaxoSmithKline Research & Development (GSK R&D), Stevenage, United Kingdom. ^[3] Medicines, Science and Technology, Protein Cellular and Structural Sciences (PCSS) Structural and Biophysical Sciences, GlaxoSmithKline Research & Development (GSK R&D), Stevenage, United Kingdom. ^[4] Medicines, Science and Technology, Protein Cellular and Structural Sciences (PCSS) Protein and Cellular Sciences, GlaxoSmithKline Research & Development (GSK R&D), Stevenage, United Kingdom. ^[5]

关键词 MAC assembly autoantibodies complement C7 complement therapy myasthenia gravis myasthenia gravis patient stratification terminal pathway